These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 38664015)

  • 1. Evaluation of Neurodegenerative Disorders with Amyloid-β, Tau, and Dopaminergic PET Imaging: Interpretation Pitfalls.
    Burkett BJ; Johnson DR; Lowe VJ
    J Nucl Med; 2024 Jun; 65(6):829-837. PubMed ID: 38664015
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Amyloid and Tau PET Imaging of Alzheimer Disease and Other Neurodegenerative Conditions.
    Rowley PA; Samsonov AA; Betthauser TJ; Pirasteh A; Johnson SC; Eisenmenger LB
    Semin Ultrasound CT MR; 2020 Dec; 41(6):572-583. PubMed ID: 33308496
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The bivariate distribution of amyloid-β and tau: relationship with established neurocognitive clinical syndromes.
    Jack CR; Wiste HJ; Botha H; Weigand SD; Therneau TM; Knopman DS; Graff-Radford J; Jones DT; Ferman TJ; Boeve BF; Kantarci K; Lowe VJ; Vemuri P; Mielke MM; Fields JA; Machulda MM; Schwarz CG; Senjem ML; Gunter JL; Petersen RC
    Brain; 2019 Oct; 142(10):3230-3242. PubMed ID: 31501889
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vivo tau PET imaging in dementia: Pathophysiology, radiotracer quantification, and a systematic review of clinical findings.
    Hall B; Mak E; Cervenka S; Aigbirhio FI; Rowe JB; O'Brien JT
    Ageing Res Rev; 2017 Jul; 36():50-63. PubMed ID: 28315409
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multimodal PET Imaging of Amyloid and Tau Pathology in Alzheimer Disease and Non-Alzheimer Disease Dementias.
    Xia C; Dickerson BC
    PET Clin; 2017 Jul; 12(3):351-359. PubMed ID: 28576172
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diagnostic Performance of RO948 F 18 Tau Positron Emission Tomography in the Differentiation of Alzheimer Disease From Other Neurodegenerative Disorders.
    Leuzy A; Smith R; Ossenkoppele R; Santillo A; Borroni E; Klein G; Ohlsson T; Jögi J; Palmqvist S; Mattsson-Carlgren N; Strandberg O; Stomrud E; Hansson O
    JAMA Neurol; 2020 Aug; 77(8):955-965. PubMed ID: 32391858
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Imaging tau and amyloid-β proteinopathies in Alzheimer disease and other conditions.
    Villemagne VL; Doré V; Burnham SC; Masters CL; Rowe CC
    Nat Rev Neurol; 2018 Apr; 14(4):225-236. PubMed ID: 29449700
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recommendations for the use of PET imaging biomarkers in the diagnosis of neurodegenerative conditions associated with dementia: SEMNIM and SEN consensus.
    Arbizu J; García-Ribas G; Carrió I; Garrastachu P; Martínez-Lage P; Molinuevo JL
    Rev Esp Med Nucl Imagen Mol; 2015; 34(5):303-13. PubMed ID: 26099942
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cerebral Microhemorrhage at MRI in Mild Cognitive Impairment and Early Alzheimer Disease: Association with Tau and Amyloid β at PET Imaging.
    Rauchmann BS; Ghaseminejad F; Mekala S; Perneczky R;
    Radiology; 2020 Jul; 296(1):134-142. PubMed ID: 32368960
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasma phosphorylated tau 217 and phosphorylated tau 181 as biomarkers in Alzheimer's disease and frontotemporal lobar degeneration: a retrospective diagnostic performance study.
    Thijssen EH; La Joie R; Strom A; Fonseca C; Iaccarino L; Wolf A; Spina S; Allen IE; Cobigo Y; Heuer H; VandeVrede L; Proctor NK; Lago AL; Baker S; Sivasankaran R; Kieloch A; Kinhikar A; Yu L; Valentin MA; Jeromin A; Zetterberg H; Hansson O; Mattsson-Carlgren N; Graham D; Blennow K; Kramer JH; Grinberg LT; Seeley WW; Rosen H; Boeve BF; Miller BL; Teunissen CE; Rabinovici GD; Rojas JC; Dage JL; Boxer AL;
    Lancet Neurol; 2021 Sep; 20(9):739-752. PubMed ID: 34418401
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Amyloid and tau imaging, neuronal losses and function in mild cognitive impairment.
    Barrio JR; Kepe V; Satyamurthy N; Huang SC; Small G
    J Nutr Health Aging; 2008 Jan; 12(1):61S-5S. PubMed ID: 18165848
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Update on PET in neurodegenerative and neuroinflammatory disorders manifesting on a behavioural level: imaging for differential diagnosis.
    Hellwig S; Domschke K; Meyer PT
    Curr Opin Neurol; 2019 Aug; 32(4):548-556. PubMed ID: 31107281
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of Diagnostic Performances Between Cerebrospinal Fluid Biomarkers and Amyloid PET in a Clinical Setting.
    Jung NY; Kim ES; Kim HS; Jeon S; Lee MJ; Pak K; Lee JH; Lee YM; Lee K; Shin JH; Ko JK; Lee JM; Yoon JA; Hwang C; Choi KU; Lee EC; Seong JK; Huh GY; Kim DS; Kim EJ
    J Alzheimers Dis; 2020; 74(2):473-490. PubMed ID: 32039853
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tau Imaging in Neurodegenerative Diseases Using Positron Emission Tomography.
    Wang YT; Edison P
    Curr Neurol Neurosci Rep; 2019 Jun; 19(7):45. PubMed ID: 31172290
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tau PET in autosomal dominant Alzheimer's disease: relationship with cognition, dementia and other biomarkers.
    Gordon BA; Blazey TM; Christensen J; Dincer A; Flores S; Keefe S; Chen C; Su Y; McDade EM; Wang G; Li Y; Hassenstab J; Aschenbrenner A; Hornbeck R; Jack CR; Ances BM; Berman SB; Brosch JR; Galasko D; Gauthier S; Lah JJ; Masellis M; van Dyck CH; Mintun MA; Klein G; Ristic S; Cairns NJ; Marcus DS; Xiong C; Holtzman DM; Raichle ME; Morris JC; Bateman RJ; Benzinger TLS
    Brain; 2019 Apr; 142(4):1063-1076. PubMed ID: 30753379
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Frequency of Biologically Defined Alzheimer Disease in Relation to Age, Sex,
    Therriault J; Pascoal TA; Benedet AL; Tissot C; Savard M; Chamoun M; Lussier F; Kang MS; Berzgin G; Wang T; Fernandes-Arias J; Massarweh G; Soucy JP; Vitali P; Saha-Chaudhuri P; Gauthier S; Rosa-Neto P
    Neurology; 2021 Feb; 96(7):e975-e985. PubMed ID: 33443136
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Usefulness of Brain Positron Emission Tomography with Different Tracers in the Evaluation of Patients with Idiopathic Normal Pressure Hydrocephalous.
    Mattoli MV; Treglia G; Calcagni ML; Mangiola A; Anile C; Trevisi G
    Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32906629
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Classics in Neuroimaging: Untangling the Role of Tau in Neurodegenerative Disorders Using Positron Emission Tomography.
    Witek JA; Brooks AF; Scott PJH
    ACS Chem Neurosci; 2022 Oct; 13(19):2778-2783. PubMed ID: 36112411
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Correlation of Alzheimer Disease Neuropathologic Staging with Amyloid and Tau Scintigraphic Imaging Biomarkers.
    Koychev I; Hofer M; Friedman N
    J Nucl Med; 2020 Oct; 61(10):1413-1418. PubMed ID: 32764121
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of tau deposition using
    Bullich S; Mueller A; De Santi S; Koglin N; Krause S; Kaplow J; Kanekiyo M; Roé-Vellvé N; Perrotin A; Jovalekic A; Scott D; Gee M; Stephens A; Irizarry M
    Alzheimers Res Ther; 2022 Jul; 14(1):105. PubMed ID: 35897078
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.